ZBH — Zimmer Biomet Holdings, Inc.

Is ZBH overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Overbought As of August 19, 2026

Zimmer Biomet Holdings, Inc. (ZBH) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Devices) last closed at $100.74. The rating moved from Neutral to Overbought on August 11, 2026.

See all overbought Healthcare stocks →

AI analysis

Zimmer Biomet is a diversified leader in orthopedic and related medical devices with structural demand from an aging population and a product roadmap benefiting from image-guided/robotic adoption. Near-term performance will track elective surgery volumes, reimbursement dynamics and margin recovery from operational improvements. Competitive intensity, payer rationalization and device-specific regulatory/litigation risks represent the main downside pressures. Public information and social signals were limited in the recent window, producing a relatively stable short-term outlook absent fresh corporate or macro developments.

Key factors

  • Leading global orthopedics franchise with broad product portfolio across joint reconstruction, trauma, spine, sports medicine and dental
  • Long-term structural demand from aging demographics and replacement surgery tailwinds supports procedure volumes over time
  • Product innovation and increasing adoption of image-guided/robotic-assisted procedures provide a growth runway for higher-value consumables and services
  • Margin recovery potential from cost-savings, supply‑chain normalization and operational efficiencies
  • Diversified geographic exposure reduces single-market dependency and provides multiple recovery levers
  • Current market backdrop is steady with balanced order flow, limiting short-term volatility from macro headlines
  • Absence of fresh EDGAR filings or social-media-driven moves in the recent window increases near-term information stability

Risks

  • Elective procedure volumes remain sensitive to macro weakness, hospital budgets and patient affordability, which could depress top-line growth
  • Intense competition from Stryker, J&J, Smith & Nephew and niche device makers can pressure pricing and share
  • Payer reimbursement pressure and strategic MA plan actions may compress margins and limit pricing power
  • Regulatory, recall or product-liability litigation risk inherent to implantable devices can create outsized costs or disruptions
  • Foreign-exchange swings and supply-chain disruptions could weigh on margins and reported results
  • Limited near-term public disclosures and muted social sentiment make short-term catalysts less visible

See today's live rating, score and targets

Members see the live hourly rating for ZBH — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.